Fat tissue injection for knee osteoarthritis compared with triamcinolone
Tests injected processed fat tissue in adults with knee osteoarthritis.
Key facts
- Who runs it
- Syntr Health Technologies, Inc.
- Where
- Irvine, United StatesSee the 2 sites
- Trial code
- Registry title
- Evaluating the Effect of Adipose Tissue Processed With the SyntrFuge™ System for Knee Osteoarthritis
- Status
- Not yet recruiting
- People taking part
- 180 people, planned
- Starts
- 1 Dec 2027
- Expected to end
- Dec 2030
- Type of study
- Interventional, 2 groups
- Treatments tested
- SyntrFuge System
- Triamcinolone Injection
- Record updated
- 20 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with knee osteoarthritis (wear of the knee joint) and knee pain for at least 3 months. They get either an injection of their own processed fat tissue or a steroid injection.
- Age
- The criteria say 35-80 years old; the record's age fields say 18 Years to 70 Years.
- Sex
- All sexes can join.
- Disease stage
- Knee osteoarthritis grade II, III or IV on the Kellgren-Lawrence scale. Chronic knee pain or symptoms for at least 3 months. Able to walk. BMI between 20 and 34.9.
- Earlier treatment
- No corticosteroid injection into the joint and no other cell therapy injection into the joint in the last 24 weeks. No immunosuppressive therapy, chemotherapy, biologics or systemic corticosteroids within 3 months before each study visit. No meniscus surgery in the previous 6 weeks. Blood thinners and anti-inflammatory drugs such as aspirin or ibuprofen are not allowed from 7 days before to 3 days after the injection.
- Biomarker or test result
- Women who could become pregnant must have a negative urine pregnancy test.
Main reasons for not taking part
- Past knee injury such as a tibial fracture or osteotomy, or osteonecrosis
- Gout, high blood fats, inflammatory arthritis or active autoimmune disease
- Blood clotting disorders, active infection or uncontrolled illness
- Pregnant, breastfeeding or planning a pregnancy
- Drug or alcohol abuse in the 36 months before screening
The registry criteria, word for word
Show all 31 criteriaShow less
Who can take part
- Subjects aged of 35-80 years old
- Patients with knee osteoarthritis grade II, III, and IV Kellgren-Lawrence
- Chronic knee pain or symptoms for at least 3 months
- BMI between 20 and 34.9
- Willing and able to read and sign the informed consent and other study materials
- Written informed consent has been obtained prior to any study-related procedures
- Written Authorization for Use and Release of Health and Research Study Information has been signed
- Subjects are ambulatory
- Subject is willing and able to comply with study instructions and commit to all follow-up visits for the duration of the study
- Females of childbearing potential must have a negative urine pregnancy test result and not be lactating
- Subject is in good general health and free of any systemic disease state or physical condition that might impair evaluation or which in the Investigator's opinion, exposes the Subject to an unacceptable risk by study participation
Who cannot take part
- Subjects with previous traumatic lesion (tibial fracture, osteothomy) of the knee
- Subjects with meniscal surgery in the previous 6 weeks
- Subjects with history or current evidence of drug or alcohol abuse within 36 months prior to screening visit
- Subjects who have received any other therapy, which, in the opinion of the investigator, could interfere with safety or efficacy evaluations
- Subjects with current enrollment in an investigational drug or device study or participation in such a study within 30 days of entry into this study
- Subjects who have undergone immunosuppressive therapy, chemotherapy, biologics or systemic corticosteroids within 3 months prior to each study visit
- No intra-articular injection of corticosteroids within the last 24 weeks
- No intra-articular injection of any other cellular therapy within the last 24 weeks
- Subjects with active infection
- Subjects with any uncontrolled systemic disease
- Subjects with a history of severe allergic/anaphylactic reactions or multiple allergies
- Subjects who have active autoimmune disease
- Subjects who have coagulation disorders
- Subjects with any other condition that, in the opinion of the investigator, makes the subject inappropriate to take part in this study
- Subjects who have received anti-coagulation, anti-platelet, or thrombolytic medications (e.g., warfarin), anti- inflammatory drugs (NSAIDs, e.g., aspirin, ibuprofen), or other substances known to increase coagulation time from 7 days pre- to 3 days post injection. A wash out period of 7 days is allowed
- Subjects with osteonecrosis
- Subjects with gout, hyperlipidemia
- Subjects without decisional capacity
- Subjects with inflammatory arthritis
- Subjects planning to become pregnant, are pregnant, or are breast-feeding
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Where in United States
- Irvine, CaliforniaHospital not named in the registryContact: Ahmed Zobi, EMBANot yet recruiting
- Irvine, CaliforniaHospital not named in the registryContact: Ahmed Zobi, EMBANot yet recruiting
About the trial
What the trial wants to find out
This is an multi-center study with the aim of evaluating the efficacy of adipose tissue processed with the SyntrFuge™ system in Orthopedic Surgery, specifically Knee Osteoarthritis. Patients will be enrolled to the treatment group with adipose tissue processed with the SyntrFuge™ system followed by an injection of autologous microsized adipose tissue in the treatment sites or Standard of Care.
The 2 groups in the trial
- SyntrFuge SystemTreatment being tested
Adipose tissue microsized via the SyntrFuge System
- Standard of CareOther group
Steroid Injection
Treatment: Triamcinolone Injection
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Multi-Center, Randomized Controlled Trial Evaluating the Effect of Adipose Tissue Processed With the SyntrFuge™ System for Knee Osteoarthritis
- Plain-language title
- Fat tissue injection for knee osteoarthritis compared with triamcinoloneGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT05526898, who can take part
- Record updated
- 20 August 2026